Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02202187 · ClinicalTrials.gov registry record · Phase 1
A Single Oral Escalating Dose Study of GSK2140944 in Healthy Volunteers
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT02202187 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 48 participants.
The verdict
NCT02202187, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
GSK2140944 belongs to the Bacterial Type II Topoisomerase Inhibitor (BTI) class of antibiotics. GSK2140944 has demonstrated in vitro and in vivo activity against Gram positive including methicillin resistant Staphylococcus aureus (MRSA) and Gram-negative pathogens associated with respiratory tract, skin and soft tissue infections including isolates resistant to existing classes of antimicrobials. This is a First Time in Human (FTIH) study to assess the safety, tolerability, and pharmacokinetics of single oral doses of GSK2140944 in healthy volunteers. This study will be a single-blind, randomized, placebo-controlled, dose-rising study in healthy subjects. The proposed single doses will range from 100 mg to 3000 mg.
Interventions
- OTHER Placebo
- DRUG GSK2140944
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2011-09-26 |
| Est. Completion | 2012-02-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02202187
The ClinicalTrials.gov registry entry for NCT02202187 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02202187 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02202187 about?
NCT02202187 is a clinical study titled "A Single Oral Escalating Dose Study of GSK2140944 in Healthy Volunteers". GSK2140944 belongs to the Bacterial Type II Topoisomerase Inhibitor (BTI) class of antibiotics. GSK2140944 has demonstrated in vitro and in vivo activity against Gram positive including methicillin resistant Staphylococcus aureus (MRSA) and Gram-negative pathogens associated with respiratory tract, ...
What is the current status of trial NCT02202187?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2011-09-26. Estimated completion is 2012-02-15.
What interventions are being tested in trial NCT02202187?
The interventions under investigation include: Placebo (OTHER), GSK2140944 (DRUG).
Who is sponsoring clinical trial NCT02202187?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.